LucidScope
AI is already answering questions about your brand. LucidScope shows you what it’s saying, and why.
LucidScope evaluates how leading AI systems respond to real-world questions about your company, products, indications, and competitors.
It maps visibility and positioning in AI-generated answers, traces the sources shaping those answers, and highlights gaps where evidence is missing, outdated, or misrepresented.
What you can do with LucidScope:
-
Perception Mapping: Compare how AI positions your brand versus key competitors.
- See how AI frames your brand versus competitors, by theme and attribute.
-
Answers Mapping: See how models answer the same stakeholder questions, and where they diverge.
- View side-by-side model answers to your key questions, with differences highlighted.
-
Source Tracing: Identify which websites and documents are shaping AI answers, and where to intervene.
- Understand which domains and documents drive the answers, and what’s missing.
-
Launch and campaign monitoring: Track changes over time across models, markets, and topics.
- Monitor shifts in positioning, key claims, and cited sources (you vs competitors).
LucidScope is part of LucidQuest’s intelligence stack, complementing our primary research, conference coverage, and wargaming capabilities.
Combined with NexusBrain (nexusbrain.io), LucidScope insights can be mapped alongside your team’s own field observations to give a complete picture of how AI is shaping your brand’s perception.
Want to see what AI is saying about your brand? Request an AI Answer Audit.
You’ll receive a short report covering Perception, Answers, Source Tracing, and Zero-click gaps.
Already evaluating tools? Test LucidScope.
Questions or feedback? Email us anytime.
February 15, 2026
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL
February 13, 2026
Public Health Video Recap—February 13, 2026
February 13, 2026
Respiratory Today—February 13, 2026
February 13, 2026
Vaccines Today—February 13, 2026
February 13, 2026
Public Health Today—February 13, 2026
February 13, 2026
Healthcare and Pharma Industry Trends H2 2025: From Innovation to Execution
February 13, 2026
Lucid Diligence Brief: Madrigal Ribo siRNA deal for MASH
February 12, 2026
Rare Disease Video Recap—February 12, 2026
February 12, 2026
Cardiovascular Video Recap—February 12, 2026
February 12, 2026
Cardiovascular Today—Februrary 12, 2026
February 12, 2026